Ticagrelor

Drug Profile

Ticagrelor

Alternative Names: AR-C 126532; AZD-6140; Brilinta; Brilique

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
  • Class Antithrombotics; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Cardiovascular disorders; Stroke
  • Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 24 Jul 2017 AstraZeneca completes a phase I trial in Sickle cell anaemia (In volunteers) in Germany (PO) (NCT03126695)
  • 11 Jul 2017 Launched for Acute coronary syndromes (Prevention) in Switzerland, Norway, United Kingdom, Czech Republic, Sweden, Portugal, Netherlands, Hungary, Greece, Germany, France, Finland, Belgium, Denmark, Spain, Poland, Ireland, Austria and Japan (PO) (AstraZeneca pipeline, July 2017)
  • 11 Jul 2017 Launched for Acute coronary syndromes in Japan (PO) (AstraZeneca pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top